Investment Thesis
LifeCore Biomedical is in severe financial distress with negative shareholders' equity (-$28.4M) and inability to cover interest expenses from operations (coverage ratio: -0.6x). The company's massive debt burden ($148.7M) relative to revenue ($23.2M) creates existential solvency risk, though positive free cash flow ($3.6M) provides temporary relief.
Strengths
- Positive operating cash flow of $4.7M despite significant net losses, suggesting non-cash charges (depreciation/R&D) are major factors
- Free cash flow generation of $3.6M with 15.4% FCF margin demonstrates some operational cash generation
- Adequate short-term liquidity with current ratio of 3.79x and cash position of $20.8M
Risks
- Negative shareholders' equity of -$28.4M indicates technical insolvency and liabilities exceeding asset values
- Interest coverage ratio of -0.6x with negative operating income ($4.7M loss) - cannot service debt from operations
- Extreme leverage with debt-to-revenue ratio of 6.4x ($148.7M debt / $23.2M revenue); minimal cash runway
- Deeply unprofitable with net margin of -64.6% and negative operating margin of -20.1%
- Pharmaceutical sector execution risk with high R&D spending and long product development cycles
Key Metrics to Watch
- Quarterly revenue trends and pipeline progress milestones
- Operating cash flow sustainability and cash burn rate
- Debt refinancing events and covenant compliance status
- Gross margin expansion trajectory
- Operating income path to positive territory
Financial Metrics
Revenue
23.2M
Net Income
-15.0M
EPS (Diluted)
$-0.43
Free Cash Flow
3.6M
Total Assets
225.5M
Cash
20.8M
Profitability Ratios
Gross Margin
19.2%
Operating Margin
-20.1%
Net Margin
-64.6%
ROE
N/A
ROA
-6.6%
FCF Margin
15.4%
Balance Sheet & Liquidity
Current Ratio
3.79x
Quick Ratio
2.41x
Debt/Equity
N/A
Debt/Assets
90.8%
Interest Coverage
-0.64x
Long-term Debt
148.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T10:57:23.276597 |
Data as of: 2026-03-31 |
Powered by Claude AI